• Veeva Systems recently announced that both Gilead Sciences and Bristol Myers Squibb have committed to using its Vault CRM platform, which includes embedded AI agents designed to enhance commercial execution in the life sciences sector.
• These enterprise wins highlight increasing adoption of Veeva’s next-generation CRM technology by major pharmaceutical clients, reinforcing its ongoing leadership in cloud-based solutions for healthcare.
• We'll explore how the addition of top pharmaceutical customers to Vault CRM strengthens Veeva's investment narrative and future growth prospects.

We've found 19 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Veeva Systems Investment Narrative Recap

To be a Veeva Systems shareholder, you have to see the long-haul case for accelerating digital transformation in life sciences, as key players commit to cloud-based platforms that improve commercial execution. The recent wins with Gilead Sciences and Bristol Myers Squibb lend further credibility to Veeva's next-generation Vault CRM, but they do not resolve the short-term concern around how quickly clients will actually migrate and use these advanced features, nor the ongoing risk that concentrated exposure to top pharma customers brings to pricing power or renewals.

Among recent developments, the August 2025 announcement that Merck also committed to Vault CRM stands out. As another top-20 pharma client adopting this platform, Merck’s choice provides tangible proof that industry adoption of Veeva’s AI-driven CRM is broadening, supporting the company’s most important growth catalyst, embedded AI agents for commercial execution, while showing how market traction can shift risks and rewards in real time.

On the other hand, investors should be aware that dependency on major pharmaceutical contracts can amplify...

Veeva Systems' outlook anticipates $4.3 billion in revenue and $1.3 billion in earnings by 2028. This projection assumes annual revenue growth of 12.8% and a $490 million increase in earnings from the current $809.9 million.

Uncover how Veeva Systems' forecasts yield a $316.71 fair value, a 13% upside to its current price.

Exploring Other Perspectives

Six fair value forecasts from the Simply Wall St Community range from US$265.94 to US$316.71 per share. With recurring pharma wins taking center stage, keep in mind that concentrated customer exposure could shape future earnings unpredictably, so review these opinions for alternate takes.

Explore 6 other fair value estimates on Veeva Systems - why the stock might be worth as much as 13% more than the current price!

Build Your Own Veeva Systems Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Veeva Systems research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Veeva Systems research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Veeva Systems' overall financial health at a glance.

Interested In Other Possibilities?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Rare earth metals are the new gold rush. Find out which 30 stocks are leading the charge.
• These 11 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.